Granules India Next On PE Buy List?
EIR Obtained For Chantilly, US Facility
Executive Summary
A recent focus on high-margin generic formulations, strong contract manufacturing business, and expected cash inflow from stake sales in joint ventures could make Granules India an attractive buy for PE funds.
You may also be interested in...
Granules India Buyback Offers Hope Amid Coronavirus Turmoil
Granules India’s buyback offer seems to be timed right. As the novel coronavirus crisis batters the Indian stock market, a 32% premium offered by the company is an attractive proposition for investors. However, its Q4 performance will see a blip on account of paracetamol export restrictions.
Granules India Buyback – Ray Of Hope During Coronavirus Turmoil?
Granules India’s buyback offer seems to be timed right. As the novel coronavirus crisis batters the Indian stock market, a 32% premium offered by the company is an attractive proposition for investors. However, its Q4 performance will see a blip on account of paracetamol export restrictions.
A Decade’s Deals In Indian Pharma Point To 2020 Trends
A look at corporate acquisitions and private equity deals in the Indian pharmaceutical industry over 2010-2019 reveals some trends, lessons and targets for possible activity in 2020.